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Mass spectrometric imaging was applied to assess compound distributions on whole-body
sections of mice after i.v. dosing of a -peptide and an -peptide control. Animals were
sacrificed at different time points (5 min, 1 h, 24 h) post-dose, providing simultaneous spatial
as well as kinetic information. As a result of this study, no detection of the -peptide control
was observed at 1 h post-dose, while retention of the -peptide was observed for longer than
24 h post-dose. (J Am Soc Mass Spectrom 2007, 18, 1921–1924) © 2007 American Society for
Mass SpectrometryMatrix-assisted laser desorption/ionization(MALDI) mass spectrometric imaging (MSI)[1] is a novel molecular imaging method,
which has already proven its value in numerous
studies, including measurement of neuropeptides
[2–4] in mouse brain sections and small organic
compound distributions measured on whole-body
tissue sections [5, 6]. However, the full potential of
this method still remains to be explored.
One area of interest is that of -peptides, oligomers
of -amino acids that adopt stable secondary structures
(helices, sheets, or turns) in solution with as few as 4 to
6 residues [7]. -Peptides display potent biological
activity in many cases, i.e., somatostatin mimics [8], and
are stable to proteases and peptidases, a feature not
generally shared by their -peptidic counterparts [9].
Previous absorption, distribution, metabolism, and ex-
cretion (ADME) studies in rats have shown -peptides
to be metabolically stable and to display tissue specific
distribution [10]. It is therefore of intense interest to
continue the study of the in vivo properties of -peptides
if they are to be pursued as potential drug candidates.
Since radio- or isotopic-labeling of compounds can often
be tedious and expensive, we postulated that mass spec-
trometry techniques could be used to determine the tissue
distribution of such parent compounds without the need
for labeling. MS techniques have also been successfully
used previously for the sequencing of -peptides [11].
As such, we envisaged using MS and the unique
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over time in animal tissue in a way not possible with
-peptides. With the high sensitivity of MALDI MS in
the peptide mass range, it is an obvious choice to apply
MALDI MS imaging to the study of the distribution of
-peptides as reported here. We therefore chose two
peptides (Figure 1), formerly used in the study of class
1 MHC peptide mimics, as representative examples of a
- and an -peptide [12].
Experimental
-Peptide 1 (H-3hGly-(S)3hArg-(S)3hAla-(S)3hAla-
(R)3hAla-(S)3hAla-(R)3hAla-(S)3hLys-OH) was pre-
pared by solid-phase–peptide-synthesis according to [12].
-Peptide 2 (Rheuma peptide Ser-Arg-His-His-Ala-Phe-
Cys-Phe-Arg) was purchased from NeoMPS (San Diego,
CA).
Three HLA-B27 transgenic mice were dosed intra-
venously (via injection into the tail vein) with 0.5 mL
of a 2 mg/mL saline solution of -peptide 1. A fourth
mouse was dosed with 0.5 mL of a 2 mg/mL saline
solution of the Rheuma -peptide 2 as a control. Mice
treated with -peptide 1 were sacrificed at 5 min, 1 h,
and 24 h post-dose (one mouse per time point) and
immediately deep frozen vertically in a mixture of
dry-ice and N-hexane at a temperature of 75 °C to
limit the risk of post-mortem diffusion of the drug.
The mouse treated with -peptide 2 was sacrificed 1 h
post-dose and frozen in an identical manner. Slow
immersion prevented cracking of the animals in the
abdominal region, a phenomenon often observed due
to freezing shock. The animals were left in the
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1922 STOECKLI ET AL. J Am Soc Mass Spectrom 2007, 18, 1921–1924freezing mixture for 30 to 40 min; thereafter, the
excess of the dry-ice/hexane mixture was rapidly
removed with the help of paper tissues before em-
bedding the mice in a semi-liquid gel of 2% sodium
carboxy-methyl-cellulose pre-cooled to 75 °C. Sag-
ittal sections of 40 m thickness were obtained at
20 °C in a CM 3600 PLC cryomicrotome (Leica
Microsystems, Nussloch, Germany) according to the
method of Ullberg [13]. The sections were rapidly
freeze-dried in a desiccator, and each section was
mounted onto two adjacent metal sample plates
fitting into the mass spectrometer. Matrix coating was
obtained by spraying 4 mL per plate of a solution of
10 mg/mL CHCA in 50:50 acetonitrile/water using a
TLC sprayer. The plates were dried for another hour
in the desiccator before analysis.
MS Image acquisition was conducted on a 4700
Proteomics Analyzer (Applied Biosystems, Framing-
ham, MA) equipped with an automatic plate loader for
multiple plates. Each plate was rastered over in a 0.5
mm  0.5 mm grid while acquiring reflectron spectra
from 100 laser shots of each position in the mass range
from m/z 200 to 2000. The two images of each animal
section were combined and analyzed in the BioMap
software (http://www.maldi-msi.org). For each sec-
tion, an ion intensity image was calculated for the
protonated ([M  H], m/z 827), sodiated ([M  Na],
m/z 849), and potassiated ([M  K], m/z 865) species.
The heme distribution (m/z 616) was calculated for
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Figure 1. Peptides used in this study: -pe
(R)3hAla-(S)3hAla-(R)3hAla-(S)3hLys-OH)
Ala-Phe-Cys-Phe-Arg).quality control.Results and Discussion
The mass spectrum shown in Figure 2 was acquired
from the kidney region of a mouse treated with the
-peptide. Strong signals are detected for the proton-
ated species as well as for the metal adducts. Figure 3
shows the mass spectrometric images of the -pep-
tide species combined with the heme distribution and
an optical image of the sections before matrix coating.
The color scale was kept constant for all the peptide
images. In the first time point, 5 min after adminis-
tration, -peptide 1 is detected in the section, with the
corresponding sodium and potassium adducts ac-
counting for a major part of the signal intensity. At
1 h post-dose, the -peptide is observed being ex-
creted through the kidney with signals from the
released urine clearly visible in the images (lower
left). The animal sacrificed at the final time point, 24 h
post-dose, still exhibits detectable -peptide concen-
trations (as the potassiated adduct) in the kidney.
This result is in good agreement with those obtained
in previous ADME experiments [10] in which it was
shown that similar radiolabeled -peptides exhibit
proteolytic and metabolic stabilities in vivo [10] and
prolonged tissue-specific half lives. In contrast to
-peptide 1, sections obtained 1 h post-dose from the
animal dosed with 2 showed no trace of the -pep-
tide, indicating that it had been quickly degraded in
the circulatory system by peptidases in the blood and
oxidative enzymes in the liver and kidneys (Figure 2).
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and This clearly demonstrates that -peptides, and similar
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to determine tissue distribution in a manner similar to
that obtained by whole body autoradioluminography
(WBAL). The overall sensitivity of MALDI-MSI depends
strongly on the tissue and on the peptide. In this study, the
detection limits for the two peptides were not exactly
determined. However, tissue spiking experiments showed
the lower limit of detection to be in the range of nanomo-
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These results also match well with the outcome of a
previous study on a similar peptide where the peptide
distribution was determined by whole-body autora-
diography [10]. Since the matrix deposition involves a
manual step, ion intensities of the high abundant heme
group are compared.
200
0
[α+H]+ 1 h
1 cm
[α+Na]+
[α+K]+
1100 1200
idney region of tissue sections of animals dosed
mass spectrometric image of the -peptide
-peptide is readily processed and was therefore
1 h 24 h
0
100
200
0
100
1 cm
f  peptide 1measured by MALDI MSI after i.v.
dney. The heme signal was evaluated to control00
/z)
the k
The
he tion o
he kid sections are shown for reference.
1924 STOECKLI ET AL. J Am Soc Mass Spectrom 2007, 18, 1921–1924Conclusion
It is obvious that the results reported here do not
present a full evaluation of the -peptide and its me-
tabolite distribution in the animals. Tissue-dependent
signal suppression was not accounted for, and there
were no internal standards added for quantification.
However this study does allow an extremely quick and
cost efficient evaluation of the compound behavior in
the animals, confirming that -peptides are stable and
distribute specifically in the tissues in vivo. While
traditional autoradiography would have taken over 1
wk to deliver a result, mass spectrometry has provided
relevant data after just a single day. This is the first
example in which an i.v. administered peptide has been
used for MS imaging.
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